Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E19.21 EPS (ttm)3.89 Insider Own0.41% Shs Outstand1.26B Perf Week-1.77%
Market Cap93.36B Forward P/E11.26 EPS next Y6.64 Insider Trans-2.57% Shs Float1.25B Perf Month-3.71%
Income4.96B PEG15.44 EPS next Q1.50 Inst Own82.60% Short Float2.02% Perf Quarter-0.37%
Sales22.72B P/S4.11 EPS this Y1.10% Inst Trans-1.28% Short Ratio1.55 Perf Half Y13.54%
Book/sh17.49 P/B4.27 EPS next Y2.71% ROA8.10% Target Price80.63 Perf Year10.75%
Cash/sh16.63 P/C4.49 EPS next 5Y1.24% ROE22.60% 52W Range60.89 - 85.97 Perf YTD14.97%
Dividend2.72 P/FCF18.80 EPS past 5Y-10.50% ROI9.50% 52W High-13.10% Beta0.71
Dividend %3.64% Quick Ratio2.90 Sales past 5Y-2.00% Gross Margin79.40% 52W Low22.70% ATR1.94
Employees11800 Current Ratio3.00 Sales Q/Q5.10% Oper. Margin19.60% RSI (14)44.14 Volatility2.03% 2.51%
OptionableYes Debt/Eq1.09 EPS Q/Q-20.70% Profit Margin21.80% Rel Volume0.31 Prev Close75.61
ShortableYes LT Debt/Eq1.00 EarningsApr 30 AMC Payout65.60% Avg Volume16.22M Price74.71
Recom2.60 SMA20-0.81% SMA50-2.06% SMA2006.38% Volume5,199,791 Change-1.19%
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Apr-20-20Downgrade BMO Capital Markets Outperform → Market Perform $79
Apr-17-20Downgrade CFRA Hold → Sell
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-20-20Upgrade Piper Sandler Neutral → Overweight $70 → $90
Mar-18-20Upgrade DZ Bank Hold → Buy $80
Mar-09-20Downgrade RBC Capital Mkts Top Pick → Outperform $86
Feb-27-20Initiated Barclays Underweight $62
Feb-06-20Downgrade Bernstein Outperform → Mkt Perform $78 → $70
Feb-05-20Downgrade Raymond James Strong Buy → Outperform $81 → $80
Jan-21-20Downgrade Guggenheim Buy → Neutral
Dec-13-19Downgrade Credit Suisse Neutral → Underperform $67 → $63
Nov-12-19Initiated SunTrust Hold $70
Oct-25-19Downgrade Maxim Group Buy → Hold
Jul-09-20 09:02AM  
03:38AM  
03:18AM  
12:35AM  
Jul-08-20 05:50PM  
04:17PM  
03:58PM  
03:36PM  
03:32PM  
02:50PM  
02:49PM  
10:22AM  
08:59AM  
06:18AM  
04:01AM  
Jul-07-20 05:45PM  
10:25AM  
09:39AM  
09:00AM  
09:00AM  
08:23AM  
Jul-06-20 09:00PM  
01:47PM  
09:56AM  
09:46AM  
09:31AM  
09:30AM  
07:14AM  
07:14AM  
07:07AM  
Jul-04-20 01:31PM  
08:13AM  
03:01AM  
03:01AM  
Jul-03-20 07:57PM  
01:23PM  
11:56AM  
09:45AM  
09:25AM  
07:56AM  
07:44AM  
Jul-02-20 05:38PM  
03:47PM  
01:12PM  
10:22AM  
09:01AM  
07:52AM  
06:30AM  
06:21AM  
Jul-01-20 06:38PM  
05:01PM  
01:55PM  
12:28PM  
12:07PM  
11:09AM  
09:50AM  
09:43AM  
09:25AM  
09:19AM  
08:30AM  
05:47AM  
Jun-30-20 09:46PM  
06:11PM  
02:34PM  
01:37PM  
01:29PM  
10:28AM  
10:14AM  
06:12AM  
06:11AM  
01:44AM  
Jun-29-20 05:45PM  
05:42PM  
05:26PM  
04:53PM  
04:15PM  
02:31PM  
02:24PM  
01:59PM  
12:45PM  
12:17PM  
11:40AM  
11:37AM  
10:56AM  
10:47AM  
10:25AM  
09:51AM  
09:23AM  
07:00AM  
Jun-28-20 04:51PM  
11:07AM  
10:51AM  
Jun-26-20 09:30PM  
03:29PM  
03:03PM  
02:08PM  
01:23PM  
10:37AM  
08:26AM  
Jun-25-20 11:05AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM